A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly
understood condition with limited treatment options. Current therapies, including a
nonabsorbable antibiotic rifaximin or diet low in fermentable oligosaccharides,
disaccharides, monosaccharides, and polyols (FODMAP), show efficacy in 50% or less of
patients. In this proposal, we will randomize IBS-D patients to receive either rifaximin or
low FODMAP dietary intervention.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Collaborator:
Michigan Institute for Clinical and Health Research (MICHR)